Ingredent :- Telmisartan + Amlodipine
Use for :- TELMIPIL AM TABLET – Used for controlling high blood pressure.
Units of :- Packing of 10 tablets strip
1. Indications
– Hypertension: TELMIPIL AM TABLET is used to treat high blood pressure, helping to reduce the risk of heart attack and stroke.
– Heart Failure: It is effective for patients with heart failure, helping to manage symptoms and improve heart function.
– Kidney Protection: TELMIPIL AM TABLET helps preserve kidney function in patients with high blood pressure or diabetes.
2. Benefits
The benefits of TELMIPIL AM TABLET include:
– Blood Pressure Control: Reduces high blood pressure, which helps prevent heart-related complications.
– Improved Heart Function: Eases the strain on the heart and improves its ability to pump blood.
– Kidney Health Protection: Helps maintain kidney function in those at risk of kidney damage.
3. Dosage and Administration
The recommended dosage is typically one tablet per day, as prescribed by your healthcare provider. Take the tablet with a glass of water.
4. Mechanism of Action
TELMIPIL AM TABLET works by relaxing blood vessels, reducing blood pressure and the strain on the heart. It also improves blood flow throughout the body.
5. Side Effects
Possible side effects include:
– Lightheadedness: Especially when standing up quickly, dizziness may occur.
– Tiredness: Fatigue or feeling weak is a common side effect.
– Nausea: Some individuals may experience an upset stomach or nausea.
6. Precautions
Before taking TELMIPIL AM TAB, inform your doctor if:
– You have any existing medical conditions, especially kidney or liver issues.
– You are pregnant or breastfeeding.
– You are on other medications, including diuretics or potassium supplements.
7. Conclusion
TELMIPIL AM TABLET is an effective treatment for managing high blood pressure, heart failure, and kidney disease. By following the prescribed dosage, you can significantly reduce your risk of cardiovascular complications and improve your overall health.
Reviews
There are no reviews yet.